Serologic Evidence of West Nile Virus Infection among Humans, Morocco
Hicham El Rhaffouli

, Mehdi El Harrak, Chafiqa Lotfi, Fatima El Boukhrissi, Tahar Bajjou, Abdelilah Laraqui, Farida Hilali, Mouna Kenfaoui, and Idriss Lahlou-Amine
Author affiliations: University Mohammed V-Souissi, Rabat, Morocco (H. El Rhaffouli, F. El Boukhrissi, T. Bajou, A. Laraqui, F. Hilali, I. Lahlou-Amine); Laboratoire Bio-Pharma, Rabat (M. El Harrak, C. Lotfi); Military Hospital Moulay Ismail, Meknes, Morocco (F. El Boukhrissi); Laboratoire Maamora, Kenitra, Morocco (M. Kenfaoui)
Main Article
Table
West Nile virus neutralizing antibody titers in human serum samples obtained during March–April 2011, Morocco
Cohort, location* |
No. samples positive/no. tested (%) |
Median ± SD |
Titer (%)
|
Weak, 18–80 |
Intermediate, 81–320 |
High, >320 |
A, Meknes |
7/150 (4.7) |
54 ± 42.5 |
5 (71.4) |
1 (14.3) |
1 (14.3) |
B, Rabat |
24/200 (12) |
54 ± 31 |
22 (91.7) |
1 (4.2) |
1 (4.2) |
C, Kenitra |
28/149 (18.8) |
95 ± 72 |
19 (67.9) |
3 (10.7) |
6 (21.4) |
Total |
59/499 (11.8) |
72 ± 41 |
46 (78) |
5 (8.5) |
9 (13.5) |
Main Article
Page created: March 16, 2012
Page updated: March 16, 2012
Page reviewed: March 16, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.